Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
up 2.16% today, likely to continue to outperform
Agree, it could be anticipation of good earning, which are released on Feb 2. But it could also be someone accumulating shares. FEYE is up 3% at the moment, while the broader markets are all down. This does not happen often.
After hours volume: 61,000
18,000 traded at the session high: 12.67
BARDA Contract announcement today:
CONCORD, Calif., Dec 19, 2016 (BUSINESS WIRE) -- Cerus Corporation CERS, -1.63% announced today that additional options totaling $10,825,555 have been exercised under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The newly exercised options include funding for in vitro pathogen inactivation and red blood cell (RBC) function studies to support FDA licensure, as well as the manufacturing of clinical trial materials needed for a Phase III trial in the continental United States.
“The exercise of these additional options reflects the substantial progress our team has made in just a few short months since initiating activities related to this important contract with BARDA,” said Dr. Laurence Corash, Cerus’ chief scientific officer. “We are working closely with the FDA to reach an agreement on the protocol design for our Phase III trial, and this additional funding ensures that we can begin preparing the necessary clinical trials materials to move forward quickly upon such agreement.”
And yet the stock price went down. Looking at the chart would suggest that shorty is pushing it down.
CHICAGO/TAMPA, Fla., Aug 26 (Reuters) - The U.S. Food and Drug Administration recommended on Friday that all blood donated in the United States and its territories be tested for Zika virus, as it moves to prevent transmission of the virus through the blood supply.
The agency said its decision to expand blood screening in the United States was based on concerns about more cases of local transmission in Florida, the growing number of travel-related infections and concerns that Zika-tainted blood could unwittingly be given to a pregnant woman, putting her unborn baby at risk of severe birth defects.
"The transfusion of a pregnant woman with blood infected with the Zika virus could have terrible consequences," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said during a conference call with reporters.
the proposed public offering of shares of its common stock previously announced on July 21, 2016. Heat’s leadership team decided to suspend the proposed public offering to explore alternative options presented to the company.
and in another filing dated 8/18/16, the public offering is back on again.
What ever the "alternative options" were, they must not have been acceptable to management. I see no other likely explanation.
With Congress Deadlocked, White House Diverts Funds to Fight Zika
http://www.nytimes.com/2016/08/12/us/politics/with-congress-deadlocked-white-house-diverts-funds-to-fight-zika.html?_r=0
Volume today over 10 million, 2x average volume. Any ideas about this?
Four people in Miami likely contracted Zika locally through mosquito bites, Florida's governor said on Friday, the first evidence that the virus tied to a rare but serious birth defect is circulating in the continental United States.
Governor Rick Scott said the state believed active transmission of the virus was occurring within an area of Miami about the size of a square mile (2.6 square kms). Testing showed that one woman and three men had been infected, Scott said.
While health officials have yet to identify mosquitoes carrying the virus, the state has ruled out other means of transmission, including travel to another country with a Zika outbreak, and sexual contact.
source: Reuters
Strange New Case Might Change What We Know About Zika
link to the story:
http://news.nationalgeographic.com/2016/07/mysterious-new-zika-transmission-utah/
Florida health officials are investigating a possible second case of the Zika virus that may have been locally transmitted. The announcement of the case, in Broward County, comes two days after the state said it was investigating a possible homegrown case in Miami-Dade County.
Florida health officials said Tuesday they were investigating a possible case of Zika that wasn't carried back by a traveler.
If it's confirmed, it would be the first evidence that Zika has spread to mosquitoes in the continental U.S. All cases up to now have been in people who traveled to Zika-affected regions or their sexual partners.
A dysfunctional Senate split along party lines has blocked a $1.1B proposal to fight the Zika virus, leaving just two weeks to reach a deal before lawmakers leave for a summer recess in the midst of mosquito season.
Democrats accused Republicans of sabotaging the legislation with provisions designed to deny new funding for Planned Parenthood clinics in Puerto Rico and ease rules on pesticide spraying.
Don't forget that Dr. Kim owns almost 2 million shares, so his interests are well aligned with that of other shareholders.
The time to raise money is when you don't need it. The fact that the new shares are At The Market is an indication of a successful strategy. Most small biotechs issue new shares at a discount to market..
MERS Vaccine Testing at Walter Reed
PUBLIC RELEASE: 16-FEB-2016
First-in-man trial of MERS vaccine begins at Walter Reed Army Institute of Research
The Walter Reed Army Institute of Research (WRAIR) began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
Price of oil is being driven down by the OPEC countries by producing at maximum capacity allegedly in order to "protect their market share", when the real reason is to inflict maximum damage to the economies of the West.
the near term catalyst is MERS. US and Saudis are working on a joint funding for MERS
Results of ASM
If the three directors (including HB) were reelected, I take this as an indication that Denner did not get the support of the largest institutional shareholders, and that HB and his cronies are still very much in control. There will be no buyout as long as HB is pulling the strings of the board.
This is remarkable failure of the board to execute their fiduciary duties. And they are probably violating several SEC regulations regarding filing of financial reports and timely disclosure of material events. I agreed with the previous post that the battling directors did not want to be in the same room, hence none attended the meeting.
Denner is silent because he lost the fight and is now figuring out his next move.
The litigation will probably begin soon.
This is looking more like Dendreon, the top executive walked away with millions and the shareholder were left holding the bag of a company in Chapter 11. What a sad story.
Annual Shareholder Meeting Notice
this is from the SEC website:
Under these requirements, the issuer must post its proxy materials on an Internet Web site and send a Notice to shareholders to inform them of the electronic availability of the proxy materials at least 40 days before the shareholders meeting. If an issuer follows this option, it must respond to shareholder requests for copies, including a shareholder’s permanent request for paper or e-mail copies of proxy materials for all shareholder meetings.
So, if they expect have the meeting late in July, as we have been informed, we should see the proxy materials in the next few days.
It is worth noting that this presentation was made by Jorge E. Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center.
MD Anderson is generally regarded as the top cancer treatment center in the country.
I agree with the view that HB speaking at a conference is a terrible idea. My guess is that he threw a hissy fit about not doing this presentation and Denner gave in to shut him up. Or it could be that the power struggle is not over and he got his way in spite of Denner.
Illegal insider trading does not surprise me. Notify the SEC? A waste of time, they are busy watching porn on their computers.
Time is of the Essence
Time is the enemy of mediocre company. And Ariad under the leadership of Berger is a mediocre company. So, I say to Mr. Denner, get Berger out of the building as soon as possible. He is the rotten apple that must be removed from the barrel before it is too late. And then give any of his loyal followers the choice of unqualified support of your plan or follow Berger out the door. The window of opportunity is shrinking and the time for action is now.
My example is Tesla. Mr. Musk is very confident that Tesla will be a leader in the market for all-electric cars. And then Toyota announced the availability of their hydrogen powered electric car which is very competitively priced compared to the Tesla and with better range. So the window of opportunity for Tesla just got much smaller.
The same thing could happen to Ariad, with advances in immunotherapy being announced almost daily a new approach could offer better a alternative than those being developed by Ariad.
Mr. Denner: Time is of the Essence
AF and theStreet are trying to help the shorts.
He has done this numerous times with other small biotechs.
Ignore him
It appears that Berger just shot himself in the foot if he hopes to keep his job. I think he gave Denner the added ammunition to insure his win of the proxy battle. Good riddance to Berger.
Twitter
I don't do Twitter, but feel free to copy any of that post that is useful.
HB vs. Sarissa
After following the discussion on how to vote on the upcoming proxy, I decided to post some thoughts on the subject.
The drama going on the the BOD and other events is quite similar to the story of Dendreon. A CEO who made terrible decisions regarding the commercialization of their only approved therapy. Who had terrible relations with the FDA resulting in a two year delay to complete additional clinical trials for Provenge. Who priced the therapy at $93,000 for a course of treatment, causing limited acceptance by prescribers. Who spent millions on creating a specially trained sales force. Who spent more millions on building four distribution facilities in key cities across the country to support their complex logistics. Who made wildly optomistic sales forcasts which never happened because while he was working on commercialization, other big pharmaceutical companies entered the market and captured a large market share for the same indication as Provenge. Who accumulated massive debt which ultimately led to Dendreon filing Chapter 11 leaving shareholders with massive losses. All while he generously enriched himself with salary and stock.
By the time that he was fired as CEO, it was too late to save the company.
I hope that Sarissa moves quickly enough to save Ariad.